LOI Deadline: February 13, 2018
Town Hall Information Session: January 31, 2018
Pharmacological Treatment for Anxiety in Children, Adolescents, and/or Young Adults – Cycle 1 2018
Notice of Upcoming PCORI Funding Announcement (PFA)
Research Initiative Highlights
The Patient-Centered Outcomes Research Institute (PCORI) seeks to fund high-quality clinical studies that compare the effectiveness of two or more pharmacological treatments for moderate to severe anxiety in children, adolescents, and/or young adults (e.g., comparisons of shorter-acting to longer-acting selective serotonin reuptake inhibitors (SSRIs) or comparisons of SSRIs to selective serotonin-norepinephrine reuptake inhibitors (SNRIs)) delivered in conjunction with cognitive behavioral therapy (CBT) or an alternative evidence-based psychological intervention.
For this PFA, PCORI is broadly interested in comparisons that are relevant and applicable to a spectrum of developmental stages represented by patients in the age range of 7 through 25 years. Applicants will be asked to clearly define the specific age range to be studied, and to provide a scientific rationale for the proposed study population.
Each proposed comparator must be clearly defined, evidence-based, and widely available, and applicants should ensure that all comparators are appropriate for the age range and disorder severity of the study population. Studies with a minimum follow-up period of one year from baseline are sought, with two years of follow-up preferred. In addition, all studies funded through this initiative must include robust sample sizes of at least 300 participants, with sufficient power demonstrated to conduct proposed analyses.
The maximum project budget is $15 million in direct costs, with a maximum project duration of five years.
This PFA preannouncement is provided to allow potential applicants additional time to identify collaborators, obtain stakeholder input on the research question, and develop responsive, high-quality proposals. Further details will be available in the full announcement to be released on January 16, 2018.